Login / Signup

A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.

Amy R RappaportChrisann KyiMonica LaneMeghan G HartMelissa Lynne JohnsonBrian S HenickChih-Yi LiaoAmit MahipalArdaman ShergillAlexander I SpiraJonathan Wade GoldmanCiaran D ScallanDesiree SchenkChristine D PalmerMatthew J DavisSonia KounlavouthLindsey KempAaron YangYaojun John LiMolly LikesAnnie ShenGregory R BoucherMilana EgorovaRobert L VeresJ Aaron EspinosaJason R JaroslavskyLauren D Kraemer TardifLindsey AcrebucheChristopher PucciaLeiliane SousaRita ZhouKyounghwa BaeJ Randolph HechtDavid P CarboneBenny JohnsonAndrew AllenAndrew R FergusonKarin Jooss
Published in: Nature medicine (2024)
Therapeutic vaccines that elicit cytotoxic T cell responses targeting tumor-specific neoantigens hold promise for providing long-term clinical benefit to patients with cancer. Here we evaluated safety and tolerability of a therapeutic vaccine encoding 20 shared neoantigens derived from selected common oncogenic driver mutations as primary endpoints in an ongoing phase 1/2 study in patients with advanced/metastatic solid tumors. Secondary endpoints included immunogenicity, overall response rate, progression-free survival and overall survival. Eligible patients were selected if their tumors expressed one of the human leukocyte antigen-matched tumor mutations included in the vaccine, with the majority of patients (18/19) harboring a mutation in KRAS. The vaccine regimen, consisting of a chimp adenovirus (ChAd68) and self-amplifying mRNA (samRNA) in combination with the immune checkpoint inhibitors ipilimumab and nivolumab, was shown to be well tolerated, with observed treatment-related adverse events consistent with acute inflammation expected with viral vector-based vaccines and immune checkpoint blockade, the majority grade 1/2. Two patients experienced grade 3/4 serious treatment-related adverse events that were also dose-limiting toxicities. The overall response rate was 0%, and median progression-free survival and overall survival were 1.9 months and 7.9 months, respectively. T cell responses were biased toward human leukocyte antigen-matched TP53 neoantigens encoded in the vaccine relative to KRAS neoantigens expressed by the patients' tumors, indicating a previously unknown hierarchy of neoantigen immunodominance that may impact the therapeutic efficacy of multiepitope shared neoantigen vaccines. These data led to the development of an optimized vaccine exclusively targeting KRAS-derived neoantigens that is being evaluated in a subset of patients in phase 2 of the clinical study. ClinicalTrials.gov registration: NCT03953235 .
Keyphrases